C19orf44 Inhibitors
C19orf44 Inhibitors are chemical compounds that directly or indirectly lead to the functional inhibition of the protein C19orf44. Staurosporine, a broad-spectrum kinase inhibitor, can impede the activity of C19orf44 by blocking the ATP binding site common to many kinases, which is a fundamental mechanism required for kinase activity. This action can lead to the direct inhibition of C19orf44 if it possesses kinase activity or relies on phosphorylation by other kinases. Another compound, triciribine, specifically targets AKT, a kinase involved in various cellular processes. Inhibition of AKT by triciribine would downregulate any C19orf44 activity that is AKT-dependent, leading to diminished function of C19orf44.
PKC is another kinase family involved in diverse signaling pathways, and both LY333531 and chelerythrine are inhibitors that target this family. LY333531 selectively inhibits PKCβ, while chelerythrine is a more general PKC inhibitor. If C19orf44 is modulated by PKC activity, these inhibitors would decrease C19orf44 activity bypreventing PKC-mediated phosphorylation events. The MEK1/2 inhibitor CI-1040 could potentially decrease C19orf44 activity by inhibiting the MAPK/ERK pathway, which is a key pathway in regulating cell proliferation and differentiation. If the function of C19orf44 is contingent upon the MAPK/ERK signaling, then interference by CI-1040 would result in reduced activation of this pathway and subsequent diminution of C19orf44 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A non-selective protein kinase inhibitor that broadly inhibits protein kinases by competing with ATP for binding. If C19orf44 is a kinase or relies on kinase activity for its function, staurosporine would inhibit its activity by preventing ATP from binding to the active site, leading to decreased C19orf44 activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
An AKT inhibitor that prevents phosphorylation and activation of AKT. If C19orf44 is an AKT substrate or is positively regulated by AKT signaling, inhibition of AKT by triciribine would result in decreased C19orf44 activity. | ||||||
LY-333,531 Hydrochloride | 169939-93-9 | sc-364215 sc-364215A | 1 mg 5 mg | $94.00 $287.00 | 6 | |
A selective inhibitor of protein kinase C beta (PKCβ). If C19orf44 is activated by PKCβ or is part of a signaling cascade that includes PKCβ, then its inhibition would result in decreased activity of C19orf44. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A Src family kinase inhibitor that also inhibits BCR-ABL. If C19orf44 activity is regulated by Src family kinases or relies on BCR-ABL signaling, dasatinib would inhibit these kinases and potentially decrease C19orf44 activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
An FGFR inhibitor that blocks the activation of the fibroblast growth factor receptor. If C19orf44 is involved in FGFR signaling pathways, inhibition by PD173074 would lead to decreased activity of C19orf44. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
An inhibitor of dihydroorotate dehydrogenase that affects pyrimidine synthesis. If C19orf44 requires pyrimidine synthesis for its activity, leflunomide would lead to a decrease in C19orf44 activity by limiting the availability of pyrimidines. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
A potent inhibitor of PKC. If C19orf44 is activated by PKC or is involved in PKC-mediated signaling, chelerythrine would lead to decreased activity of C19orf44 by inhibiting PKC. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that prevents AKT activation. If C19orf44 operates downstream of PI3K/AKT signaling, inhibition by LY294002 would lead to reduced activity of C19orf44. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that prevents mTORC1 activation. If C19orf44 is regulated by mTOR signaling, rapamycin would inhibit this pathway and decrease the activity of C19orf44. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
An inhibitor of the TGF-β receptor. If C19orf44 is involved in TGF-β signaling, SB431542 would inhibit this pathway and decrease the activity of C19orf44. | ||||||